BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Breast cancer immunotherapy: Current and novel approaches. Int Immunopharmacol 2021;98:107886. [PMID: 34153663 DOI: 10.1016/j.intimp.2021.107886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Zhou C, Zhang S, Chen X, Liu J, Xu F, Liang W. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol 2022;12:939249. [DOI: 10.3389/fonc.2022.939249] [Reference Citation Analysis]
2 Zeng R, Peng B, Peng E, Chen Z. Downregulated Copper Homeostasis-Related Gene FOXO1 as a Novel Indicator for the Prognosis and Immune Response of Breast Cancer. Journal of Immunology Research 2022;2022:1-13. [DOI: 10.1155/2022/9140461] [Reference Citation Analysis]
3 Rojas F, Hernandez S, Lazcano R, Laberiano-fernandez C, Parra ER. Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research. Front Oncol 2022;12:889886. [DOI: 10.3389/fonc.2022.889886] [Reference Citation Analysis]
4 Zheng G, Jia L, Yang AG. Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment. Front Immunol 2022;13:791975. [PMID: 35185887 DOI: 10.3389/fimmu.2022.791975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang J, Pan S, Jian C, Hao L, Dong J, Sun Q, Jin H, Han X. Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice. Front Immunol 2021;12:819405. [PMID: 35069604 DOI: 10.3389/fimmu.2021.819405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Siva V, Murugan A, Shameem AS, Priya MU, Thangarasu S, Athimoolam S, Bahadur SA. Design and supramolecular architecture of stepped molecular aggregation in monochloroacetate salt of 2-aminopyridine: Its bacterial and cancer inhibitory properties. Journal of Molecular Structure 2022;1250:131888. [DOI: 10.1016/j.molstruc.2021.131888] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Xu L, Hu Y, Liu W. Pyroptosis-Mediated Molecular Subtypes are Characterized by Distinct Tumor Microenvironment Infiltration Characteristics in Breast Cancer. JIR 2022;Volume 15:345-62. [DOI: 10.2147/jir.s349186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Liu W, Xia L, Xia Z, Chen L. Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients. Genes 2022;13:88. [DOI: 10.3390/genes13010088] [Reference Citation Analysis]
9 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Shramova EI, Shilova MV, Ryabova AV, Dzhalilova DS, Zolotova NA, Telegin GB, Deyev SM, Proshkina GM. Barnase*Barstar-guided two-step targeting approach for drug delivery to tumor cells in vivo. J Control Release 2021;340:200-8. [PMID: 34740723 DOI: 10.1016/j.jconrel.2021.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Oner G, Önder S, Karatay H, Ak N, Tükenmez M, Müslümanoğlu M, İğci A, Dincçağ A, Özmen V, Aydiner A, Yavuz E, Cabioğlu N. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. World J Surg Oncol 2021;19:264. [PMID: 34474671 DOI: 10.1186/s12957-021-02361-9] [Cited by in F6Publishing: 6] [Reference Citation Analysis]